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Objective. To examine risk factors for false positive HIV enzyme immunoassay (EIA) testing at delivery. Study Design.Ar e v i e wo f
pregnant women who delivered at Parkland Hospital between 2005 and 2008 was performed. Patients routinely received serum
HIV EIA testing at delivery, with positive results conﬁrmed through immunoﬂuorescent testing. Demographics, HIV, hepatitis B
surface antigen (HBsAg), and rapid plasma reagin (RPR) results were obtained. Statistical analyses included Pearson’s chi-square
and Student’s t-test. Results. Of 47,794 patients, 47,391 (99%) tested negative, 145 (0.3%) falsely positive, 172 (0.4%) positive, and
86(0.2%)equivocalormissingHIVresults.ThepositivepredictivevalueofEIAwas54.3%.Patientswithfalsepositiveresultswere
more likely nulliparous (43% versus 31%, P<0.001) and younger (23.9 ± 5.7v e r s u s2 6 .2 ± 5.9 years, P<0.001). HIV positive
patients were older than false positive patients and more likely positive for HBsAg and RPR. Conclusion. False positive HIV testing
at delivery using EIA is associated with young maternal age and nulliparity in this population.
1.Introduction
The Centers for Disease Control and Prevention (CDC)
and United States Preventive Services Task Force (USPSTF)
recommend universal HIV screening for all pregnant women
entering prenatal care [1, 2]. This screening enables HIV-
infectedwomenandtheirinfantstobeneﬁtfromappropriate
and timely interventions such as antiretroviral medications.
When the recommended antiretroviral and obstetric inter-
ventions are used, a woman who knows of her HIV infection
early in pregnancy now has a less than 2% chance of
delivering an HIV-infected infant. Without intervention, this
risk is approximately 25% in the United States [3–6].
Testing for HIV began in 1985 with the introduction
of the enzyme immunoassay (EIA). In order to account for
false positive results using screening tests in a low-prevalence
population, conﬁrmatory testing has been implemented
using a Western blot or immunoﬂuorescence assay. In a low-
prevalence population, the false positive rate using the EIA
is increased compared to a high-prevalence population, and
the positive predictive value of any test will always depend on
the prevalence of the condition in the population tested. In
testing performed by the CDC, the EIA positive predictive
value ranges from 71 to 83% in populations with HIV
p r e v a l e n c ef r o m0 . 5t o1 %[ 7].
Pregnancy has been observed to be associated with
false positive HIV testing. Some investigators believe that
the presence of alloantibodies account for the increased
false positive rate associated with pregnancy, transfusions,
transplantation, and autoimmune diseases [8]. However,
risk factors speciﬁc to pregnancy that account for this are
poorly understood. Conversely, a recent large retrospective
study found that the false positive HIV EIA rate was lower
in pregnant women compared to nonpregnant individuals2 Journal of Pregnancy
(0.14% versus 0.21%) [9]. Our objective was to determine
if any maternal characteristics correlated with false positive
HIV EIA testing at delivery.
2.MaterialsandMethods
This was a review of all women who delivered at Parkland
Memorial Hospital in Dallas, Tex, from October 1, 2005
through September 30, 2008. All women routinely received
serum HIV testing at their initial prenatal visit and at time of
presentation to labor and delivery for delivery via the opt-
out approach with the Abbott Commander HIV AB HIV-
1/HIV-2 (rDNA) EIA (Abbott Laboratories, Abbott Park,
Ill). HIV test results performed at the time of delivery
were analyzed in this study. A woman was considered HIV
negative if EIA testing was negative. Positive test results were
conﬁrmed with the ﬂuorognost immunoﬂuorescent assay
(IFA) HIV-1 (Sanochemia Corp, Stamford, Conn, USA).
Women were considered to be falsely positive if EIA results
were positive and the IFA was negative. Women delivered
in this time period were identiﬁed through the obstetric
operations database and linked to the pathology database for
HIV, hepatitis B surface antigen (HBsAg), and rapid plasma
reagin (RPR) results. Maternal characteristics, including
race, parity, age, singleton versus multiple gestation, and a
diagnoses of diabetes or hypertension were obtained using
the obstetrics operations database. Laboratory results drawn
28 days prior to delivery through seven days after delivery
were included.
The study was approved by the Institutional Review
Board at the University of Texas Southwestern Medical
Center. Categorical data were reported as frequencies, and
statistical signiﬁcance was determined using χ2 analysis.
Two-group comparisons were made using Student’s t-test. P
values less than 0.05 were considered statistically signiﬁcant.
Statistical analyses were performed using SAS, Version 9.2
(SAS Institute, Cary, NC).
3. Results
A total of 47,794 women were identiﬁed who delivered
during the study time frame. Demographic and obstetrical
characteristics of the patient population are shown in
Table 1. Compared to HIV negative patients, false positive
patients were more likely to be nulliparous (43% versus 31%,
P<0.001)andyounger(meanage23.9±5.7versus26.2±5.9,
P<0.001). HIV positive patients were signiﬁcantly older
than false positive patients (27.4 versus 23.9, P<0.001) and
HIV negative patients (27.4 versus 26.2, P = 0.012).
Of the 47,794 women, 47,391 (99%) were HIV negative,
145 (0.3%) had a false positive test, 172 (0.4%) were
true positives, and 86 (0.2%) tested equivocal or were
missing HIV results. The speciﬁcity of the HIV EIA test
was 99.7% with a positive predictive value of 54.3%. The
sensitivity of the EIA test was presumed to be near 100%,
as the false negative rate using the EIA has been previously
demonstrated to be negligible in studies performed by the
manufacturer [10].
Table 2 shows the prevalence of diabetes, hypertension,
hepatitis B, and results of syphilis testing in the study
population. HIV positive women were more likely to test
positive for hepatitis B surface antigen (1% versus 0%, P =
0.002) and RPR (2% versus 0%, P = 0.02). There was
no signiﬁcant diﬀerence in the prevalence of diabetes or
hypertension between the three groups. There was also no
signiﬁcantdiﬀerenceintherateofHBsAgandRPRpositivity
between the HIV negative and false positive groups.
When evaluating the interaction between nulliparity
and age, there is a signiﬁcant correlation between the two
variables; that is, parous patients are likely to be older and,
therefore, nulliparity and age are not independent predictors
of HIV false positivity. However, when the HIV testing
groups (positive, false positive, negative) are stratiﬁed by
parity,thecomparisonofageacrossthethreegroupsremains
signiﬁcant only in nulliparous women (Table 3, P = 0.0003).
The interaction between parity and age means that the
diﬀerence in age between nulliparous and parous women is
diﬀerent depending on the HIV status. For example, in the
HIV positive group the nulliparous and parous women are
closer in age than in the false positive group.
4. Comment
This was the ﬁrst population-based study to evaluate risk
factors for HIV false positivity in pregnant women pre-
senting for delivery at a large urban institution. We found
that younger and nulliparous women were more likely to
have false positive testing using the HIV EIA. The observed
positive predictive value (PPV) of 54.3% was lower than
the previously reported by the CDC (PPV 71–83%) in a
nonpregnant population [7], suggesting that pregnancy may
be associated with a higher rate of false positivity. The low
positive predictive value of the HIV EIA in our study may
have been impacted by the relatively low HIV prevalence
(0.4%) in our population. This information could be useful
for counseling women who test positive for HIV at delivery
and emphasizes the limitations of EIA testing if used as
a rapid test to determine the need for intrapartum and
neonatal antiretroviral prophylaxis.
The false positive rates of currently available rapid HIV
tests have been reported to be much lower than has been
found with EIA testing in this study. Tung et al. evaluated the
HIV false positive rate in over 900 pregnant women, most of
whom were Hispanic, using both the EIA and a rapid point-
of-care (POCT) test, OraQuick [11]. They found that while
there were no false positive tests with the OraQuick, there
were seven false positives using the EIA (PPV 100% versus
35.7%). In the Mother-Infant Rapid Intervention at Delivery
(MIRIAD) study, Jamieson et al. found that the PPV of the
OraQuick test was 90% while the PPV of the EIA was 74%
[12, 13].
Current recommendations by the CDC and the Ameri-
can College of Obstetricians and Gynecologists include rapid
HIV screening for women presenting to labor and delivery
withundocumentedHIVstatusandforrepeatHIVtestingin
thethirdtrimesterforwomenathighriskorwholiveinareasJournal of Pregnancy 3
Table 1: Demographic and obstetric characteristics of HIV positive, false positive, and negative women.
Characteristic Positive
N = 172
False positive
N = 145
Negative
N = 47391
P
Positive versus
false positive
Positive versus
negative
False positive
versus negative
Age: mean ± std 27.4 ± 6.2 23.9 ± 5.7 26.2 ± 5.9 <0.001 0.012 <0.001
Age <0.001 0.021 0.002
<18 2 (1) 16 (11) 2494 (5)
18–35 152 (88) 124 (86) 41412 (87)
>35 18 (10) 5 (3) 3485 (7)
Race <0.001 <0.001 0.102
Black 116 (67) 19 (13) 4422 (9)
White 16 (9) 8 (6) 1955 (4)
Hispanic 38 (22) 118 (81) 39975 (84)
Other 2 (1) 0 (0) 1039 (2)
Nulliparous 45 (26) 63 (43) 14488 (31) 0.001 0.210 <0.001
Parity 0.002 0.009 0.004
0 45 (26) 63 (43) 14488 (31)
1 53 (31) 47 (32) 14732 (31)
2 35 (20) 21 (14) 10690 (23)
3 19 (11) 9 (6) 4893 (10)
>3 20 (12) 5 (3) 2588 (5)
Multiple gestation 1 (1) 0 (0) 531 (1) 0.358 0.502 0.200
Data expressed as N (%) or mean ± standard deviation.
Table 2: Comorbidities, hepatitis B, and RPR results in HIV positive, false positive, and negative women.
Characteristic Positive
N = 172
False positive
N = 145
Negative
N = 47391
P
Positive versus
false positive
Positive versus
negative
False positive
versus negative
Diabetes 13 (8) 8 (6) 3015 (6) 0.467 0.521 0.677
Hypertension 20 (12) 16 (11) 4164 (9) 0.868 0.189 0.340
HBsAg 0.002 <0.001 0.580
No result 12 (7) 0 (0) 224 (0.5)
Negative 158 (92) 145 (100) 47038 (99)
Positive 2 (1) 0 (0) 129 (0.3)
RPR 0.020 <0.001 0.618
No result 5 (3) 0 (0) 31 (0.07)
Nonreactive 163 (95) 145 (100) 47078 (99)
Reactive 4 (2) 0 (0) 282 (0.6)
Data expressed as N (%).
with high HIV prevalence [7, 14, 15]. A woman testing
preliminarily positive for HIV in labor should be counseled
thatshemayhaveHIVinfectionandthatherneonatemaybe
exposed, and immediate antiretroviral prophylaxis should be
recommended without waiting for conﬁrmatory test results.
The results of our study may aid in counseling women
if they test preliminarily positive for HIV using the EIA,
while awaiting conﬁrmatory testing results. It remains to be
determined whether the same risk factors for false positive
HIV EIA testing apply to the POCT tests used in a real life
setting.
Our study found that the positive predictive value of EIA
testing was only 54.3% and that younger nulliparous women
were more likely to test falsely positive. The reasons for these
ﬁndings are not entirely clear. Importantly, our data may
represent the real world performance of the EIA testing in
a large obstetric population-based setting. Investigators also
have noted a signiﬁcant relationship between inﬂuenza vac-
cination and false positive screening for HIV antibodies [16–
18]. A potential reason for this cross reactivity is that there
are similarities in homology between the transmembrane
domains of the inﬂuenza envelope protein hemagglutinin4 Journal of Pregnancy
Table 3: HIV testing groups stratiﬁed by age and parity.
Nulliparous
HIV result
≤19 years
N = 4925
>19 years
N = 9671 P
Positive 10 (0.20) 35 (0.36)
False positive 35 (0.71) 28 (0.29) 0.0003
Negative 4880 (99.1) 9608 (99.4)
Parous
HIV result
≤19 years
N = 1568
>19 years
N = 31544 P
Positive 7 (0.45) 120 (0.38)
False positive 6 (0.38) 76 (0.24) 0.5
Negative 1555 (99.2) 31348 (99.4)
Data expressed as N (%).
and the HIV-1 envelope proteins [19]. In our population,
there were no signiﬁcant diﬀerences in age or parity and
inﬂuenza vaccination acceptance rates (unpublished data).
There were several limitations to our study. Women in
our study were from a single institution, with a predomi-
nantly Hispanic background, and therefore the results may
notbeapplicabletoallpopulations.Reasonsforfalsepositive
HIV serology may vary depending on the geographical
region. While we did ﬁnd a signiﬁcant association between
young age, nulliparity, and HIV false positive testing, our
study does not have the capability to identify a causal
relationship or explain why this association may exist.
In addition, our study cannot address if these same risk
factors for false positive testing apply to all other HIV
tests. Further studies are needed to conﬁrm our ﬁndings,
elucidate the biological mechanisms for increased HIV EIA
false positivity in young, nulliparous women, and compare
this conventional testing method with contemporary rapid
screening assays, including POCT.
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